10
IRUS Total
Downloads

Antioxidant lipoic acid ligand-shell gold nanoconjugates against oxidative stress caused by α-Synuclein aggregates

File Description SizeFormat 
d0na00688b.pdfPublished version2.35 MBAdobe PDFView/Open
Electronic Supplementary Information.pdfSupporting information901.76 kBAdobe PDFView/Open
Title: Antioxidant lipoic acid ligand-shell gold nanoconjugates against oxidative stress caused by α-Synuclein aggregates
Authors: Piersimoni, ME
Teng, X
Cass, AEG
Ying, L
Item Type: Journal Article
Abstract: Gold nanoparticle is becoming a promising platform for the delivery of drugs to treat neurodegenerative diseases. Parkinson’s disease, associated with the aggregation of α-synuclein, is a condition that results in dysfunctional neuronal cells leading to their degeneration and death. Oxidative stress has been strongly implicated as a common feature in this process. The limited efficacy of the traditional therapies and the development of associated severe side effects present an unmet need for preventive and adjuvant therapies. The organosulfur compound lipoic acid, naturally located in the mitochondria, plays a powerful antioxidative role against oxidative stress. However, the efficacy is limited by its low physiological concentration, and the administration is affected by its short half-life and bioavailability due to hepatic degradation. Here we exploited the drug delivery potential of gold nanoparticles to assemble lipoic acid, and administered the system to SH-SY5Y cells, a cellular model commonly used to study Parkinson’s disease. We tested the nanoconjugates, termed GNPs-LA, under an oxidative environment induced by gold nanoparticle/α-synuclein conjugates (GNPs-α-Syn). GNPs-LA were found to be biocompatible and capable of restoring the cell damage caused by high-level reactive oxygen species generated by excessive oxidative stress in the cellular environment. We conclude that GNPs-LA may serve as a promising drug delivery vehicle conveying antioxidant molecules for the treatment of Parkinson’s disease.
Issue Date: 1-Dec-2020
Date of Acceptance: 21-Oct-2020
URI: http://hdl.handle.net/10044/1/83550
DOI: 10.1039/d0na00688b
ISSN: 2516-0230
Publisher: Royal Society of Chemistry
Start Page: 5666
End Page: 5681
Journal / Book Title: Nanoscale Advances
Volume: 2
Issue: 12
Copyright Statement: © The Royal Society of Chemistry 2020. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence http://creativecommons.org/licenses/by/3.0/. Material from this article can be used in other publications provided that the correct acknowledgement is given with the reproduced material.
Sponsor/Funder: The Leverhulme Trust
Funder's Grant Number: RPG-2015-345
Keywords: Science & Technology
Physical Sciences
Technology
Chemistry, Multidisciplinary
Nanoscience & Nanotechnology
Materials Science, Multidisciplinary
Chemistry
Science & Technology - Other Topics
Materials Science
PARKINSONS-DISEASE
LIPID-PEROXIDATION
NANOPARTICLES
DOPAMINE
THERAPY
DAMAGE
MODEL
DRUG
Publication Status: Published
Online Publication Date: 2020-10-21
Appears in Collections:Chemistry
Biological and Biophysical Chemistry
National Heart and Lung Institute
Faculty of Medicine
Faculty of Natural Sciences



This item is licensed under a Creative Commons License Creative Commons